Literature DB >> 29055077

Genetic association and phenotypic correlation of TLR4 but not NOD2 variants with Tunisian inflammatory bowel disease.

Sawsan Feki1, Dorra Bouzid1, Olfa Abida1, Lassaad Chtourou2, Nesrine Elloumi1, Amina Toumi1, Hend Hachicha1, Ali Amouri2, Nabil Tahri2, Hatem Masmoudi1.   

Abstract

OBJECTIVE: The common association between NOD2/CARD15 and TLR4 gene variants with inflammatory bowel disease (IBD) has not been replicated in all studies. We studied the polymorphism of these two genes in Tunisian patients with IBD.
METHODS: Polymorphisms of NOD2 (R702W, G908R and L1007fs) and TLR4 (Asp299Gly and Thr399Ile) genes were analyzed in 106 patients with IBD (68 with ulcerative colitis [UC], 38 with Crohn's disease [CD]) and 160 healthy controls using polymerase chain reaction-restriction fragment length polymorphism. Genotypes and phenotypes were correlated.
RESULTS: The mutated allele of TLR4-Thr399Ile was strongly associated with IBD (9.4% in IBD, 7.4% in UC and 13.2% in CD vs 2.5% in controls; P = 0.0004, 0.014 and 0.00006, respectively). Heterozygous genotypes were significantly more frequent in patients with IBD (17.0%), UC (14.7%) and CD (21.1%) than in controls (5.0%) (P = 0.0012, 0.012 and 0.001, respectively). Interestingly, the wild genotype was found to be protective (odds ratio 0.24). The mutated allele of TLR4-Asp299Gly was more frequent in controls (6.8%) than in patients with IBD (2.9%). A phenotypic correlation of Asp299Gly-AG genotype with arthritis in UC patients was detected (P = 0.003). Regarding the NOD2 gene, the common variations studied were not polymorphic and there was no genetic association with IBD.
CONCLUSION: The TLR4-Thr399Ile variant was strongly associated with susceptibility to IBD, whereas TLR4-Asp299Gly seems to play a role in the clinical expression of UC. The rarity and non-association of NOD2 mutations with IBD may reveal a genetic characteristic of the population in our region.
© 2017 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Crohn disease; NOD2/CARD15, single nucleotide polymorphism; TLR4, ulcerative colitis; inflammatory bowel diseases

Mesh:

Substances:

Year:  2017        PMID: 29055077     DOI: 10.1111/1751-2980.12552

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  5 in total

1.  Non-radiographic axial spondyloarthritis in Tunisia: main characteristics and detailed comparison with ankylosing spondylitis.

Authors:  Kawther Ben Abdelghani; Yosra Gzam; Alia Fazaa; Saoussen Miladi; Meriem Sellami; Leila Souabni; Selma Kassab; Selma Chekili; Leith Zakraoui; Ahmed Laater
Journal:  Clin Rheumatol       Date:  2020-09-24       Impact factor: 2.980

2.  IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4.

Authors:  Xiaowei Chen; Wenwen Sun; Risheng Lin; Zhiming Huang; Weichang Chen
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

Review 3.  Crohn's disease in low and lower-middle income countries: A scoping review.

Authors:  Ruma Rajbhandari; Samantha Blakemore; Neil Gupta; Alma J Adler; Christopher Allen Noble; Sara Mannan; Klejda Nikolli; Alison Yih; Sameer Joshi; Gene Bukhman
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

4.  Brain Magnetic Resonance Imaging Features of Nicotine-Dependent Individuals and Its Correlation with Polymorphisms of Dopamine D Receptor Gene.

Authors:  Hongfeng Liu; Lixin Guan; Ying Nie; Qi Li; Jiting Xue; Yong Yang; Shengzhong Rong; Jun Liang; Yanzhong Guan; Fengguo Zhai; Yanhai Ren; Ziyi An; Zesong Dong; Zhixue Han
Journal:  Contrast Media Mol Imaging       Date:  2022-08-24       Impact factor: 3.009

Review 5.  A Review on Inflammatory Bowel Diseases: Recent Molecular Pathophysiology Advances.

Authors:  Maheeba Abdulla; Nafeesa Mohammed
Journal:  Biologics       Date:  2022-09-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.